Keryx Biopharmaceuticals (KERX) Receives Average Recommendation of “Hold” from Brokerages

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.13.

KERX has been the subject of a number of analyst reports. BidaskClub upgraded Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, April 11th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. ValuEngine raised shares of Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $5.00 target price on shares of Keryx Biopharmaceuticals in a research report on Monday, June 25th.

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Keryx Biopharmaceuticals by 1.9% during the 4th quarter. BlackRock Inc. now owns 6,097,948 shares of the biopharmaceutical company’s stock worth $28,356,000 after buying an additional 112,381 shares in the last quarter. Millennium Management LLC bought a new position in shares of Keryx Biopharmaceuticals during the 1st quarter worth approximately $3,847,000. Geode Capital Management LLC lifted its position in shares of Keryx Biopharmaceuticals by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 912,179 shares of the biopharmaceutical company’s stock worth $4,241,000 after buying an additional 19,003 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Keryx Biopharmaceuticals by 3.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 536,951 shares of the biopharmaceutical company’s stock worth $2,197,000 after buying an additional 17,620 shares in the last quarter. Finally, Summit Trail Advisors LLC lifted its position in shares of Keryx Biopharmaceuticals by 355.3% during the 1st quarter. Summit Trail Advisors LLC now owns 333,803 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 260,485 shares in the last quarter. 61.53% of the stock is currently owned by hedge funds and other institutional investors.

Keryx Biopharmaceuticals traded down $0.25, reaching $3.86, during mid-day trading on Friday, Marketbeat.com reports. 961,592 shares of the company traded hands, compared to its average volume of 1,231,972. The company has a market capitalization of $500.18 million, a P/E ratio of -4.39 and a beta of 2.65. The company has a debt-to-equity ratio of -3.96, a quick ratio of 1.87 and a current ratio of 2.66. Keryx Biopharmaceuticals has a fifty-two week low of $3.30 and a fifty-two week high of $8.07.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). The company had revenue of $21.75 million for the quarter, compared to analyst estimates of $21.80 million. sell-side analysts forecast that Keryx Biopharmaceuticals will post -0.55 earnings per share for the current fiscal year.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Featured Article: What does EPS mean?

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply